Activated STING in a vascular and pulmonary syndrome.

BACKGROUND The study of autoinflammatory diseases has uncovered mechanisms underlying cytokine dysregulation and inflammation. METHODS We analyzed the DNA of an index patient with early-onset systemic inflammation, cutaneous vasculopathy, and pulmonary inflammation. We sequenced a candidate gene, TMEM173, encoding the stimulator of interferon genes (STING), in this patient and in five unrelated children with similar clinical phenotypes. Four children were evaluated clinically and immunologically. With the STING ligand cyclic guanosine monophosphate-adenosine monophosphate (cGAMP), we stimulated peripheral-blood mononuclear cells and fibroblasts from patients and controls, as well as commercially obtained endothelial cells, and then assayed transcription of IFNB1, the gene encoding interferon-β, in the stimulated cells. We analyzed IFNB1 reporter levels in HEK293T cells cotransfected with mutant or nonmutant STING constructs. Mutant STING leads to increased phosphorylation of signal transducer and activator of transcription 1 (STAT1), so we tested the effect of Janus kinase (JAK) inhibitors on STAT1 phosphorylation in lymphocytes from the affected children and controls. RESULTS We identified three mutations in exon 5 of TMEM173 in the six patients. Elevated transcription of IFNB1 and other gene targets of STING in peripheral-blood mononuclear cells from the patients indicated constitutive activation of the pathway that cannot be further up-regulated with stimulation. On stimulation with cGAMP, fibroblasts from the patients showed increased transcription of IFNB1 but not of the genes encoding interleukin-1 (IL1), interleukin-6 (IL6), or tumor necrosis factor (TNF). HEK293T cells transfected with mutant constructs show elevated IFNB1 reporter levels. STING is expressed in endothelial cells, and exposure of these cells to cGAMP resulted in endothelial activation and apoptosis. Constitutive up-regulation of phosphorylated STAT1 in patients' lymphocytes was reduced by JAK inhibitors. CONCLUSIONS STING-associated vasculopathy with onset in infancy (SAVI) is an autoinflammatory disease caused by gain-of-function mutations in TMEM173. (Funded by the Intramural Research Program of the National Institute of Arthritis and Musculoskeletal and Skin Diseases; ClinicalTrials.gov number, NCT00059748.).

[1]  Mark E Flanagan,et al.  Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. , 2014, Journal of medicinal chemistry.

[2]  R. Goldbach-Mansky,et al.  Monogenic autoinflammatory diseases: disorders of amplified danger sensing and cytokine dysregulation. , 2013, Rheumatic diseases clinics of North America.

[3]  J. English,et al.  The skin and hypercoagulable states. , 2013, Journal of the American Academy of Dermatology.

[4]  Zhijian J. Chen,et al.  Cyclic GMP-AMP Is an Endogenous Second Messenger in Innate Immune Signaling by Cytosolic DNA , 2013, Science.

[5]  Zhijian J. Chen,et al.  Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway , 2013, Science.

[6]  K. Ishii,et al.  DNA damage sensor MRE11 recognizes cytosolic double-stranded DNA and induces type I interferon by regulating STING trafficking , 2013, Proceedings of the National Academy of Sciences.

[7]  Steven M Holland,et al.  JAKs and STATs in immunity, immunodeficiency, and cancer. , 2013, The New England journal of medicine.

[8]  J. Graf Rheumatic manifestations of cocaine use , 2013, Current opinion in rheumatology.

[9]  R. Vance,et al.  STING and the innate immune response to nucleic acids in the cytosol , 2012, Nature Immunology.

[10]  G. Barber,et al.  STING manifests self DNA-dependent inflammatory disease , 2012, Proceedings of the National Academy of Sciences.

[11]  John H Livingston,et al.  Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature , 2012, Nature Genetics.

[12]  G. Cheng,et al.  Structural analysis of the STING adaptor protein reveals a hydrophobic dimer interface and mode of cyclic di-GMP binding. , 2012, Immunity.

[13]  J. Casanova,et al.  Inborn errors of human JAKs and STATs. , 2012, Immunity.

[14]  R. Goldbach-Mansky,et al.  Immunology in clinic review series; focus on autoinflammatory diseases: update on monogenic autoinflammatory diseases: the role of interleukin (IL)‐1 and an emerging role for cytokines beyond IL‐1 , 2012, Clinical and experimental immunology.

[15]  A. Paller,et al.  Mutations in proteasome subunit β type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity. , 2012, Arthritis and rheumatism.

[16]  G. Barber,et al.  Autoimmunity initiates in nonhematopoietic cells and progresses via lymphocytes in an interferon-dependent autoimmune disease. , 2012, Immunity.

[17]  A. Bowie,et al.  Cytosolic DNA sensors regulating type I interferon induction. , 2011, Trends in immunology.

[18]  G. Firestein,et al.  The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon , 2011, Annals of the rheumatic diseases.

[19]  Y. Crow Type I interferonopathies: a novel set of inborn errors of immunity , 2011, Annals of the New York Academy of Sciences.

[20]  D. Standley,et al.  A mutation in the immunoproteasome subunit PSMB8 causes autoinflammation and lipodystrophy in humans. , 2011, The Journal of clinical investigation.

[21]  Yong‐jun Liu,et al.  The helicase DDX41 senses intracellular DNA mediated by the adaptor STING in dendritic cells , 2011, Nature Immunology.

[22]  N. Niikawa,et al.  Proteasome assembly defect due to a proteasome subunit beta type 8 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome , 2011, Proceedings of the National Academy of Sciences.

[23]  A. Garg,et al.  PSMB8 encoding the β5i proteasome subunit is mutated in joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy syndrome. , 2010, American journal of human genetics.

[24]  James W. Jacobberger,et al.  Major Differences in the Responses of Primary Human Leukocyte Subsets to IFN-β , 2010, The Journal of Immunology.

[25]  A. Bowie,et al.  IFI16 is an innate immune sensor for intracellular DNA , 2010, Nature Immunology.

[26]  G. Trinchieri,et al.  Type I interferon: friend or foe? , 2010, The Journal of experimental medicine.

[27]  S. Akira,et al.  The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors , 2010, Nature Immunology.

[28]  W. Mccune,et al.  A Distinct Subset of Proinflammatory Neutrophils Isolated from Patients with Systemic Lupus Erythematosus Induces Vascular Damage and Synthesizes Type I IFNs , 2010, The Journal of Immunology.

[29]  J. Szilasiová,et al.  Cutaneous vasculitis associated with interferon beta-1b treatment for multiple sclerosis. , 2009, Clinical neuropharmacology.

[30]  Seth L Masters,et al.  Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*). , 2009, Annual review of immunology.

[31]  T. Heidmann,et al.  Trex1 Prevents Cell-Intrinsic Initiation of Autoimmunity , 2008, Cell.

[32]  B. Williams,et al.  Novel interferon‐β‐induced gene expression in peripheral blood cells , 2007, Journal of leukocyte biology.

[33]  D. Barnes,et al.  Heterozygous mutations in TREX1 cause familial chilblain lupus and dominant Aicardi-Goutieres syndrome. , 2007, American journal of human genetics.

[34]  Annalisa Ballarini,et al.  Familial chilblain lupus, a monogenic form of cutaneous lupus erythematosus, maps to chromosome 3p. , 2006, American journal of human genetics.

[35]  R. Medzhitov,et al.  Type I interferons in host defense. , 2006, Immunity.

[36]  W. Beuthien,et al.  Vasculitic complications of interferon-α treatment for chronic hepatitis C virus infection: case report and review of the literature , 2005, Clinical Rheumatology.

[37]  A. Edefonti,et al.  Purpura of the ears: a distinctive vasculopathy with circulating autoantibodies complicating long‐term treatment with levamisole in children , 1999, The British journal of dermatology.

[38]  J. Goodwin,et al.  Symmetrical peripheral gangrene. , 1974, Archives of surgery.

[39]  J. Lindenmann,et al.  Virus interference. I. The interferon , 1957, Proceedings of the Royal Society of London. Series B - Biological Sciences.

[40]  Y. Crow Aicardi-Goutières syndrome. , 2013, Handbook of clinical neurology.

[41]  P. Merkel,et al.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. , 2013, Arthritis and rheumatism.